Live
Clinical OMICsNatural Compounds in Cranberry Juice May Enhance Antibiotic Treatment of UTIsClinical OMICsBreast Cancer Prevention Drug Endoxifen Shows Promise at Low DosesFierceBiotechPassage launches strategic review and 75% layoffs after gene therapy path blocked by FDAIlluminaFinal Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBCEndpoints NewsFDA search for new CBER head focused on small group of final candidatesFierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and ChinaBioPharma DiveCelcuity strengthens case for ASCO-spotlighted breast cancer drugEndpoints NewsSupreme Court restores mifepristone access by mailClinical OMICsBiomarker of Epigenetic Aging Could Signal DepressionAmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.comFierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 winSamsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce Pharma
Endpoints News Mar 20, 2026

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation

Original
Body unavailable. Use the original source.